Clinical Trial Update: Feasibility Study of Exenatide by Continuous Subcutaneous Infusion [Phase 1]

View source ↗

Summary

Phase 1 feasibility study of exenatide delivered by continuous subcutaneous infusion for obesity has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• BYETTA (Exenatide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Obesity | Phase 1 | Status: COMPLETED